(Q37868637)

24 August 2017

1 reference

title

Guidelines for supportive care in multiple myeloma 2011. (English)

1 reference

24 August 2017

1 reference

2

1 reference

24 August 2017

4

Shirley D'Sa

1 reference

24 August 2017

John A Snowden

1

1 reference

24 August 2017

John Ashcroft

3

1 reference

24 August 2017

Timothy Littlewood

5

1 reference

24 August 2017

Eric Low

6

1 reference

24 August 2017

Helen Lucraft

7

1 reference

24 August 2017

Rhona Maclean

8

1 reference

24 August 2017

Sylvia Feyler

9

1 reference

24 August 2017

Guy Pratt

10

1 reference

24 August 2017

Jennifer M Bird

11

1 reference

24 August 2017

Haemato-oncology Task Force of British Committee for Standards in Haematology and UK Myeloma Forum

12

1 reference

24 August 2017

language of work or name

English

0 references

publication date

22 April 2011

1 reference

British Journal of Haematology

24 August 2017

published in

1 reference

24 August 2017

volume

154

1 reference

24 August 2017

issue

1

1 reference

24 August 2017

page(s)

76-103

1 reference

The use of cognitive interviewing methodology in the design and testing of a screening tool for supportive and palliative care needs

24 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The total challenge of cancer pain in supportive and palliative care

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bortezomib-induced peripheral neuropathy in multiple myeloma: a comprehensive review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Early mortality after diagnosis of multiple myeloma: analysis of patients entered onto the United kingdom Medical Research Council trials between 1980 and 2002--Medical Research Council Adult Leukaemia Working Party

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Neurotoxicity of bortezomib therapy in multiple myeloma: a single-center experience and review of the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Opioid Therapy for Chronic Pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

5% lidocaine medicated plaster versus pregabalin in post-herpetic neuralgia and diabetic polyneuropathy: an open-label, non-inferiority two-stage RCT study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The role of aspirin in the prevention of thrombotic complications of thalidomide and anthracycline-based chemotherapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The LANSS Pain Scale: the Leeds assessment of neuropathic symptoms and signs.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thalidomide- and lenalidomide-associated thromboembolism among patients with cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Using screening tools to identify neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Curcumin (diferuloylmethane) down-regulates the constitutive activation of nuclear factor-kappa B and IkappaBalpha kinase in human multiple myeloma cells, leading to suppression of proliferation and induction of apoptosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Topical 5% lidocaine (lignocaine) medicated plaster treatment for post-herpetic neuralgia: results of a double-blind, placebo-controlled, multinational efficacy and safety trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

UK Myeloma Forum (UKMF) and Nordic Myeloma Study Group (NMSG): guidelines for the investigation of newly detected M-proteins and the management of monoclonal gammopathy of undetermined significance (MGUS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Guidelines for the diagnosis and management of multiple myeloma 2011.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Evaluation of anaemia in patients with multiple myeloma and lymphoma: findings of the European CANCER ANAEMIA SURVEY.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A pilot study evaluating the safety and efficacy of modafinal for cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Recombinant human erythropoiesis-stimulating agents and mortality in patients with cancer: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

EORTC guidelines for the use of erythropoietic proteins in anaemic patients with cancer: 2006 update

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bisphosphonate-induced osteonecrosis of the jaws: prospective study of 80 patients with multiple myeloma and other malignancies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Recent major improvement in long-term survival of younger patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Efficacy and safety of once-weekly bortezomib in multiple myeloma patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Gabapentin for neuropathic cancer pain: a randomized controlled trial from the Gabapentin Cancer Pain Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bortezomib-induced peripheral neurotoxicity: still far from a painless gain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thalidomide sensory neurotoxicity: a clinical and neurophysiologic study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The longitudinal relationship of hemoglobin, fatigue and quality of life in anemic cancer patients: results from five randomized clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Randomised trial of intravenous immunoglobulin as prophylaxis against infection in plateau-phase multiple myeloma. The UK Group for Immunoglobulin Replacement Therapy in Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire for patients with bone metastases: the EORTC QLQ-BM22.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Efficacy and safety of transdermal fentanyl and sustained-release oral morphine in patients with cancer and chronic non-cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Feasibility of exercise during treatment for multiple myeloma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The management of cancer-related breakthrough pain: recommendations of a task group of the Science Committee of the Association for Palliative Medicine of Great Britain and Ireland.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A myeloma paraprotein with specificity for platelet glycoprotein IIIa in a patient with a fatal bleeding disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Treatment of POEMS syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Follow-up care for young adult survivors of cancer: lessons from pediatrics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Features and risk factors of peripheral neuropathy during treatment with bortezomib for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Acquired von Willebrand syndrome: an underdiagnosed and misdiagnosed bleeding complication in patients with lymphoproliferative and myeloproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Prevention of venous thromboembolism: the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Guidelines on the diagnosis and management of AL amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Curcumin: from ancient medicine to current clinical trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Efficacy and safety of darbepoetin alfa in anaemic patients with lymphoproliferative malignancies: a randomized, double-blind, placebo-controlled study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Efficient assessment of neuropathic pain drugs in patients with small fiber sensory neuropathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Recent developments: management of pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bortezomib therapy alone and in combination with dexamethasone for previously untreated symptomatic multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Percutaneous vertebroplasty in the treatment of malignant spine disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Pharmacology and treatment of neuropathic pains

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Multiple myeloma: causes and consequences of delay in diagnosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Antithrombotic therapy for venous thromboembolic disease: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Gabapentin and an opioid combination versus opioid alone for the management of neuropathic cancer pain: a randomized open trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A 3-day short course of palifermin before HDT reduces toxicity and need for supportive care after autologous blood stem-cell transplantation in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Deep vein thrombosis after monoclonal gammopathy of undetermined significance and multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Review of 1027 patients with newly diagnosed multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Sublingual administration of fentanyl to cancer patients is an effective treatment for breakthrough pain: results from a randomized phase II study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Pyridoxine (vitamin B6) neurotoxicity: enhancement by protein-deficient diet

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Revised European best practice guidelines for the management of anaemia in patients with chronic renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Current evidence for a genetic modulation of the response to analgesics

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thalidomide-dexamethasone compared with melphalan-prednisolone in elderly patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Molecular mechanisms of cancer pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Should prophylactic granulocyte-colony stimulating factor be used in multiple myeloma patients developing neutropenia under lenalidomide-based therapy?

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Vertebroplasty in multiple myeloma: outcomes in a large patient series

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Recommendations for influenza and pneumococcal vaccinations in people receiving chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thromboembolic events with lenalidomide-based therapy for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The role of radiation therapy in the management of plasma cell tumors

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A systematic review and meta-analysis of the pharmacological treatment of cancer-related fatigue

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Complementary and alternative medicine use in colorectal cancer patients in seven European countries.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Complementary and alternative medicine use in patients with haematological malignancies in Europe.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Unmet supportive care needs, psychological well-being and quality of life in patients living with multiple myeloma and their partners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bleeding symptoms and coagulation abnormalities in 337 patients with AL-amyloidosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Green tea component, catechin, induces apoptosis of human malignant B cells via production of reactive oxygen species

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Opioids in pain management of blood-related malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Peripheral neuropathy in monoclonal gammopathy of undetermined significance: prevalence and immunopathogenetic studies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Challenges in the development of novel treatment strategies for neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Randomized, double-blind, placebo-controlled trial of recombinant human erythropoietin, epoetin Beta, in hematologic malignancies.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thalidomide for treatment of multiple myeloma: 10 years later

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A prospective, randomized trial for the prevention of mucositis in patients undergoing hematopoietic stem cell transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Ascorbic acid inhibits antitumor activity of bortezomib in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Management of oral and gastrointestinal mucositis: ESMO clinical recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The effectiveness of commonly used mouthwashes for the prevention of chemotherapy-induced oral mucositis: a systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Cancer pain: part 1: Pathophysiology; oncological, pharmacological, and psychological treatments: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medicine and the Royal College of General Practitioners

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Cancer pain: part 2: physical, interventional and complimentary therapies; management in the community; acute, treatment-related and complex cancer pain: a perspective from the British Pain Society endorsed by the UK Association of Palliative Medici

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Oxycodone for cancer-related pain: meta-analysis of randomized controlled trials.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A phase 2 study of bortezomib in relapsed, refractory myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Single-agent bortezomib in previously untreated multiple myeloma: efficacy, characterization of peripheral neuropathy, and molecular correlations with response and neuropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Immunogenicity of vaccination against influenza, Streptococcus pneumoniae and Haemophilus influenzae type B in patients with multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Oral opioid therapy for chronic peripheral and central neuropathic pain

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Role of gamma globulin for immunoprophylaxis in multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Elevated urokinase-type plasminogen activator level and bleeding in amyloidosis: case report and literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bisphosphonate-related osteonecrosis: genetic and acquired risk factors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Innovative pain therapy with a fixed combination of prolonged-release oxycodone/naloxone: a large observational study under conditions of daily practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

When is cancer pain mild, moderate or severe? Grading pain severity by its interference with function.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Screening studies for fatigue and laboratory correlates in cancer patients undergoing treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Tolerability and effects of two formulations of oral transmucosal fentanyl citrate (OTFC; ACTIQ) in patients with radiation-induced oral mucositis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Specific killing of multiple myeloma cells by (-)-epigallocatechin-3-gallate extracted from green tea: biologic activity and therapeutic implications

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Responsiveness of the Harris Hip Score and the SF-36: five years after total hip arthroplasty.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Assessing persistent cancer pain: a comparison of current pain ratings and pain recalled from the past week

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Surgical approaches to metastatic spine disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Review of peripheral neuropathy in plasma cell disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Monoclonal gammopathy of undetermined significance and multiple myeloma are associated with an increased incidence of venothromboembolic disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Meta-analysis: effect of prophylactic hematopoietic colony-stimulating factors on mortality and outcomes of infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Methylnaltrexone for opioid-induced constipation in advanced illness

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Patient assessment of effectiveness and satisfaction with traditional medicine, globalized complementary and alternative medicines, and allopathic medicines for cancer in Pakistan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Gabapentin monotherapy for the treatment of chemotherapy-induced neuropathic pain: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Herbal compounds and toxins modulating TRP channels

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thalidomide-dexamethasone as primary therapy for advanced multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Fentanyl buccal tablet for the treatment of breakthrough pain in opioid-tolerant patients with chronic cancer pain: A long-term, open-label safety study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Meta-analysis of dose-fractionation radiotherapy trials for the palliation of painful bone metastases.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Deep vein thrombosis in patients with multiple myeloma treated with thalidomide and chemotherapy: effects of prophylactic and therapeutic anticoagulation

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Thrombotic complications in patients with newly diagnosed multiple myeloma treated with lenalidomide and dexamethasone: benefit of aspirin prophylaxis

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Report of three cases of circulating heparin-like anticoagulants

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Natural History of Osteonecrosis of the Jaw in Patients With Multiple Myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

The Total Neuropathy Score as an assessment tool for grading the course of chemotherapy-induced peripheral neurotoxicity: comparison with the National Cancer Institute-Common Toxicity Scale

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2011.08574.X

Nutrition support for bone marrow transplant patients

21 January 2018

1 reference

30 December 2023

https://opencitations.net/index/api/v1/citations/10.1002/14651858.CD002920.PUB3

Identifiers

DOI

10.1111/J.1365-2141.2011.08574.X

1 reference

24 August 2017

1 reference